Why Do Health Systems Not Fund Supervised Exercise Programmes for Intermittent Claudication?  by Popplewell, M.A. & Bradbury, A.W.
Eur J Vasc Endovasc Surg (2014) 48, 608e610EDITORIALWhy Do Health Systems Not Fund Supervised Exercise Programmes for
Intermittent Claudication?In August 2012 the UK National Institute for Heath and
Care Excellence (NICE) published Clinical Guideline (CG)
147 on Peripheral Arterial Disease (PAD).1 The recom-
mendations within CG 147 were based on a comprehen-
sive analysis of the available evidence by a multi-
disciplinary team of experts from vascular surgery, inter-
ventional radiology, vascular nursing, podiatry, primary
care, and other stake-holder groups.2 The process was
supported by NICE-appointed experts in systematic re-
views and statistical/health economic analyses who were
working according to well-deﬁned NICE policies and pro-
cedures.3 CG 147 was supported by the publication of
NICE Pathways (Fig. 1) and Quality Standards to assist
primary/secondary clinicians and healthcare purchasers
(termed commissioners in the UK) to facilitate the imple-
mentation of the recommendations across the UK National
Health Service (NHS).4,5
Regarding the management of intermittent claudica-
tion (IC), the commonest clinical manifestation of PAD,
NICE CG 147 made strong recommendations regarding
the primacy of a supervised exercise programme in the
treatment hierarchy (Table 1), while QS 52 recommends
that “people with intermittent claudication are offered a
supervised exercise programme (SEP)”.5 NICE is a
powerful body within the UK, whose work drives and is
driven by national health planning and policy at the
highest level; for example, the National Cardiovascular
Outcomes Strategy and the NHS Outcomes Framework
2013e2014.6,7
Why then has all this work not (as yet) led to a major
change in the management of IC across the UK, that is away
from early endovascular or surgical revascularisation and
towards best medical treatment (BMT) and SEP, with
intervention being reserved for a relatively small group of
patients who fail to improve or progress despite these
evidence-based non-interventional measures? Why is it that
NHS (as opposed to research) funded SEPs are still absent
from most UK hospitals (NHS Trusts), while at the same time
NHS Commissioners appear to be placing no limits on the
number of interventions performed for IC? Although this is
a complex issue, the reasons seem to fall into three main
categories.1078-5884/$ e see front matter  2014 European Society for Vascular
Surgery. Published by Elsevier Ltd. All rights reserved.
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NICE recognises that further research is needed to explore the
effects of SEP on quality of life (QoL) and walking behaviour.
The CG 147 research question 4.2 reads “What is the clinical
and cost effectiveness of supervised exercise programmes
compared with unsupervised exercise for treating people
with intermittent claudication, taking into account the effects
on long-term outcomes and continuing levels of exercise?”.
Although a recent Cochrane review showed statistically sig-
niﬁcant improvements in maximal treadmill walking distance
with SEP (as compared with unsupervised programmes), no
improvement in QoL was observed.8 Another small study has
shown improvement in QoL when SEP was combined with
percutaneous angioplasty.9
So, doubts about the beneﬁts of SEP over unsupervised
exercise, as well as uncertainty regarding the optimum form
of SEP, may well be inhibiting NHS Commissioners from
investing in non-interventional treatments for IC.
Other concerns may include: (i) most randomised trials
are small and often under-powered, at least when it comes
to sub-group analyses. This has led to calls for more
“rigorous and fully powered trials” in exercise therapies.10
(ii) SEP has not been standardised (either in nature or
duration), thereby making comparisons difﬁcult.11,12 A
recent review article has also highlighted the variability in
delivery observed in many randomised trials.13 (iii) A variety
of different outcomes measures have been used (treadmill,
various walking tests, patient reported outcomes measures
based on QoL, health economic metrics such as cost per
QALY) and these have resulted in different conclusions be-
ing drawn.14e18 (iv) Will the patients turn up and continue
to do so? The potential loss of clinical and cost-effectiveness
associated with non-attendance is unpopular with pur-
chasers. (v) What happens when the patients stop exer-
cising (under supervision)? Are the observed improvements
maintained or will the patients quickly revert to baseline
levels of activity?19,20 Only limited evidence is available
attesting to the long-term beneﬁts of SEP.21 (vi) How many
patients are actually suitable for SEP? Many PAD patients
have other comorbidities such as chronic obstructive air-
ways disease and coronary disease that may make them
unsuitable and may increase the risks.22
PATIENTS DON’T LIKE SEP
It could also be reasonably argued that the lifestyle choices,
behaviours, and personality traits that lead people to
Figure 1. NICE PAD Pathway: management of intermittent
claudication.4
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could not be less likely to comply with, and beneﬁt from,
BMT and SEP. It is well documented that patients with PAD
have reduced levels of physical activity.23
Clinical experience suggests that a signiﬁcant number of
patients affected by IC are looking for a “quick ﬁx”, such as aTable 1. NICE CG 147 recommendations regarding IC.1
1.5.1 Offer a supervised exercise programme (SEP) to all people
with intermittent claudication (IC).
1.5.2 Consider providing a SEP for people with IC which in-
volves: 2 hours of supervised exercise a week for a 3-month
period and encourages people to exercise to the point of
maximal pain.
1.5.3 Offer angioplasty for treating people with SEP only when:
advice on the beneﬁts of modifying risk factors has been
reinforced (see recommendation 1.2.1) and a SEP has not led to
a satisfactory improvement in symptoms and imaging has
conﬁrmed that angioplasty is suitable for the person.
1.5.4 Do not offer primary stent placement for treating people
with IC caused by aorto-iliac disease (except complete occlu-
sion) or femoropopliteal disease.
1.5.5 Consider primary stent placement for treating people
with IC caused by complete aorto-iliac occlusion (rather than
stenosis).
1.5.6 Use bare metal stents when stenting is used for treating
people with IC.
1.5.7 Offer bypass surgery for treating people with severe
lifestyle-limiting IC only when: angioplasty has been unsuc-
cessful or is unsuitable and imaging has conﬁrmed that bypass
surgery is appropriate for the person.
1.5.8 Use an autologous vein whenever possible for people
with intermittent claudication having infra-inguinal bypass
surgery.
1.5.9 Consider naftidrofuryl oxalate for treating people with IC
starting with the least costly preparation, only when SEP has
not led to satisfactory improvement and the person prefers not
to be referred for consideration of angioplasty or bypass sur-
gery. Review progress after 3e6 months and discontinue naf-
tidrofuryl oxalate if there has been no symptomatic beneﬁt.tablet or an intervention, which places as little burden on
them as possible in terms of both taking responsibility for
their health as well as the physical effort of complying with
treatment. Being brought to and from hospital by an
ambulance for a day case angioplasty under local anaes-
thetic may seem much more preferable to weeks of trav-
elling to a SEP clinic where they will be repeatedly criticised
for failing to quit smoking and lose weight!24 The corollary
of that is that when, almost inevitably in the face of
continued non-compliance with BMT, the angioplasty or
bypass fails, the “blame” can be placed ﬁrmly on the clini-
cian and not the patient.
CLINICIANS DON’T LIKE SEP?
Last, but by nomeans least, asking vascular surgeons (VS) and
interventional radiologists (IR) to embrace the NICE CG 147
guidelines on IC may be akin to asking “Turkeys to vote for
Christmas”. Although within the UK NHS (where the over-
whelming proportion of interventions for IC are performed)
VS and IR are salaried (and are not therefore working in a
competitive, fee-for-service, environment), a steady and
signiﬁcant reduction in lower limb interventions as a result of
CG 147 would have profound effects upon workload, liveli-
hood, work force planning, and training.VS and IR havemade
career choices because they like, and professionally validate
themselves by, exercising the skills they have acquired to
perform interventions. Often the more complex and ‘avant
garde’ the intervention, the better the clinician’s kudoswithin
the hospital and at conferences, as well as in terms of income.
One cannot also discount the powerful inﬂuence of amedical
devices industry that makes huge sums of money across the
world (often in countries that can ill afford it) out of PAD
interventions that often have little or no credible, unbiased
evidence of clinical and cost-effectiveness. No wonder then
that the manufacturers of balloons, stents and stent-grafts
are happy to expend very signiﬁcant time and resources
identifying susceptible “key opinion leaders” who will pro-
mote their use for IC and brief against the already unpopular
non-interventional therapies.
CONCLUSIONS
In conclusion, despite clear evidence that signiﬁcant clinical
beneﬁt can be achieved within accepted “willingness to pay”
thresholds, and the publication of UK national guidelines,
purchasers, patients, and clinicians seem reluctant to accept
BMT and SEP as a ﬁrst line therapy for the overwhelming
majority of patients affected by IC. Although further RCTs
would be helpful (and are certainly required), the authors
would suggest that themain blockage to adopting SEP is not a
lack of evidence (many other areas of vascular practice are
enthusiastically embraced despite a much lower level of sci-
entiﬁc justiﬁcation), but overcoming patient resistance and
professional self-interest. Re-imbursement drives practice
and until hospitals are rewarded for running a successful SEP,
and at the same time appropriately dis-incentivised from
offering intervention until BMT and SEP have been tried and
given a chance towork, it seems unlikely that therewill be the
610 Editorialparadigm shift in the management of IC that the NICE CG 147
has called for.
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